Although the levels of CD1d were significantly different between the AML and ALL patients, no significant difference was identified between CD3+CD56+ T lymphocyte cytotoxicity and the levels of CD1d (P>0.05; Table VII). This evidence concerns the gene NCAM1 and acute myeloid leukemia.